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1. Introduction 
1.1 TGF-β ligands, receptors and smads 
Transforming Growth Factor-beta (TGF-β), a cytokine that is expressed in a variety of 
normal tissues, including the lung (Bartram & Spear, 2004; Jakowlew et al., 1995, 1998; 
Kang et al., 2000; Montuenga et al., 1998), exerts diverse effects on a wide variety of 
cellular processes, including proliferation, differentiation, and apoptosis (Elliot & Blobe, 
2005; Massagué, 1998). More than sixty different TGF-β family members have been 
identified in various oraganisms, with at least 29 of these proteins being encoded in 
humans. Among the many proteins in the TGF-β superfamily are four TGF-β ligands, five 
activins, eight bone morphogenetic proteins (BMP), and 15 growth and differentiation 
factors (GDF). Three TGF-β isoforms have been identified in humans, including TGF-β1, 
TGF-β2, and TGF-β3, with each being a homodimeric polypeptide with a molecular 
weight of 25-kDa. All three TGF-β isoforms are initially synthesized as 55-kDa pro-
proteins that consist of an amino-terminal pro-region and a carboxy-terminal mature 
region (Gentry et al., 1988). The pro-region facilitates necessary dimerization of the pro-
proteins for future activity. TGF-β is secreted in a latent, inactive form in which the 12.5-
kDa carboxyl-terminal 112 amino acid-long mature form is non-covalently associated with 
the 80-kDa Latency-Associated Peptide (LAP) amino-terminal remainder (Barcellos-Hoff, 
1996; Barcellos-Hoff & Ewan, 2000). The LAP forms a complex with the 12.5-kDa TGF-β to 
keep it inactive (Arndjelovic et al., 2003; Stander et al., 1999). This complex is referred to 
as the small latent TGF-β complex. The small latent TGF-β complex may associate with 
members of the latent TGF-β-binding protein (LTBP) family to form the large latent TGF-β 
complex (Öklü & Hesketh, 2000). The liberation of TGF-β from the latent complexes is 
referred to as activation (Annes et al., 2003). The precise steps that are involved in 
liberation of the bioactive dimer are not completely understood, but may involve cleavage 
of the LTBP or LAP or both (Hyytiäinen et al., 2004).  
Active TGF-β exerts its effects with specific high affinity receptors. In mammals, five TGF-β 
superfamily type I receptors and seven type II receptors have been identified (Derynck et al., 
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2001; Massagué, 2000). The TGF-β type I and type II receptors are structurally related 
transmembrane glycoproteins that consist of an extracellular N-terminal ligand-binding 
domain with more than ten cysteine residues that regulate the dimeric structure, a 
transmembrane region, and a C-terminal serine/threonine kinase domain. The type I 
receptors, but not type II receptors, have a highly conserved region that is rich in glycine 
and serine residues, referred to as the GS domain, in the juxtamembrane domain next to the 
N-terminus of the kinase domain. The GS domain is a target for the type II receptor kinase, 
and upon its phosphorylation on specific serine and threonine residues, the type I receptor 
becomes activated (Heldin et al., 1997; Massagué, 2000). Being downstream of the type II 
receptor, the type I receptor plays an important role in determining the specifity of 
intracellular signals. The type I and II receptors exist as homodimers at the cell surface in the 
absence of ligands, but have an inherent heteromeric affinity for each other. Only select 
combinations of type I and II receptors act as ligand-binding signaling complexes. The 
molecular basis of the selectivity of the type I-type II receptor interactions remains poorly 
understood, but the structural complement at the interface may help define the selectivity of 
the receptor combinations. Most of the TGF-β ligands bind with high affinity to the type I 
receptor, also known as activin receptor-like kinase (ALK), or to the type II receptor, while 
others bind efficiently only to heteromeric receptor combinations.  
The intracellular signal transduction triggered by the kinase activity of TGF-β involves the 
phosphorylation of Smad family proteins and in turn, complex changes in the 
transcriptional regulation of various response genes. The Smad family proteins include 
Smad 1, 2, 3, 4, 5, 7, and 8. The Smads are divided into three subclasses depending on their 
structure and function: the receptor-regulated Smads (R-Smads), common-mediator Smad 
(Co-Smad), and inhibitory Smads (I-Smads). In general, the R-Smads, Smads 2 and 3, 
function downstream of the TGF-β ligands, while Smads 1, 5, and 8 are downstream of 
members of the BMP and GDF subfamilies of ligands. Smads 1, 2, 3, 5, and 8 are direct 
substrates for the TGF-β type I receptor kinase, whereas Co-Smad, Smad 4, participates in 
Smad complex formation. Smads 6 and 7, the I-Smads, interfere with TGF-β-induced Smad-
dependent signal transduction (Park, 2005; Whitman, 1997). Activation of cell surface 
receptors by ligands leads to phosphorylation of the R-Smads at two serine residues in a 
SSXS motif at their extreme C-termini. This phosphorylation allows the R-Smads to form 
both homomeric and heteromeric complexes with Smad4 that accumulate in the nucleus. 
There, they are directly involved in transcriptional regulation of target genes in cooperation 
with other transcription factors. 
Signaling by TGF-β is mediated by a ligand-induced heteromeric complex of two types of 
transmembrane serine/threonine kinase receptors designated as TGF-β type I receptor 
(TGF-β RI) and type II receptor (TGF-β RII). Initial ligand binding to constitutively active 
TGF-β RII is followed by recruitment of TGF-β RI into the heteromeric complex. Subsequent 
phosphorylation of TGF-β RI at its GS-domain and activation is mediated by TGF-β RII and 
leads to activation of TGF-β RI. Upon this activating phosphorylation, TGF-β RI 
phosphorylates the receptor-activated Smad proteins (R-Smads), Smad2 and Smad3, which 
form a heteromeric complex with the co-Smad, Smad4, and enter the nucleus. In the 
nucleus, the Smad complex associates with other transcription factors for transcriptional 
activation of specific target genes (Massagué and Wotton, 2000; ten Dijke et al., 2000; Wrana 
and Attisano, 2000). 
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1.2 Tumor suppressor activity of TGF-β 
TGF-β was originally called one of the most potent polypeptide growth inhibitors isolated 
from natural sources (Moses et al., 1985; Tucker et al., 1984). When it was demonstrated that 
TGF-β could act as an autocrine negative growth regulator in the several different epithelial 
cell lines, it was hypothesized that TGF-β may act as an inhibitor of tumor progression, a 
tumor suppressor (Artega et al., 1990; Glick et al., 1989). The identification and 
characterization of the intermediates in the TGF-β signaling pathway, comprised of the 
genes and proteins for the TGF-β receptors and Smads, has increased our understanding of 
the role of TGF-β as a tumor suppressor. The involvement of the TGF-β signaling pathway 
in tumor suppression is shown by mutations in the genes that encode the TGF-β receptors 
and Smad proteins in human tumors. 
The gene for TGF-β RII is frequently mutated in colon carcinoma cells from patients with 
hereditary non-polyposis colorectal cancer that also show microsatellite instability, as well 
as in gastric cancers and gliomas (Chung et al., 1996; Izumoto et al., 1997; Markowitz et al., 
1995). A specific region of adenine nucleotides in the coding region of TGF-β RII is prone to 
mutation in these patients from germline defects in their capacity for DNA mismatch repair. 
The nucleotide deletions or additions result in a shortened version of TGF-β RII that cannot 
participate in signaling transduction (Lu et al., 1996). However, the TGF-β RII gene is not 
mutated in other types of carcinoma with microsatellite instability, including breast, liver, 
pancreatic, and endometrial carcinoma (Abe et al., 1996; Kawate et al., 1999; Vincent et al., 
1996), while, a somatic frameshift mutation in the polyadenine tract of the TGF-β RII gene 
does occur in some endometrial cancer patients (Parekh et al., 2002). Missense and 
inactivating mutations in TGF-β RII have also been detected in colon cancers that do not 
exhibit microsatellite instability (Grady et al., 1999). Expression of TGF-β RII can be 
decreased in some cases of carcinoma, including head and neck squamous carcinoma, breast 
carcinoma, and laryngeal carcinoma (Eisma et al., 1996; Franchi et al., 2001; Gobbi et al., 
1999). Re-expression of TGF-β RII in carcinoma cells that have either lost expression of TGF-
β RII or show reduced TGF-β RII expression can inhibit the ability to become malignant.  
Although less common than in TGF-β RII, mutations in TGF-β RI also occur in patients with 
a variety of cancers, including ovarian cancers, metastatic breast cancers, T-cell lymphomas, 
and head and neck cancer metastases (Chen et al., 1998, 2001; Goggins, 1998; Schiemann et 
al., 1999). Patients with ovarian cancer show a high frequency of mutations of TGF-β RI 
(Chen et al., 2001), while expression of TGF-β RI is transcriptionally repressed by DNA 
methylation in cells from patients with gastric cancer (Kang et al., 1999). Over-expression of 
TGF-β RI in colon carcinoma cells with low levels of TGF-β RI also inhibits tumor 
progression as with TGF-β RII (Wang et al., 1996). Mutations in TGF-β RI do not appear to 
be associated with TGF-β RII mutations; such mutations suggest that these TGF-β receptors 
may function as tumor suppressors. 
Decreased TGF-β receptor expression or availability of TGF-β receptors at the cell surface 
may allow tumor cells to escape the growth inhibitory function of TGF-β (Kim et al., 2000). 
Expression of the TGF-β receptors in tumor cells may also be reduced by altered levels or 
activities of transcription factors that are required for expression of TGF-β RII, such as the 
Ets transcription factor. Hypermethylation of CpG islands in the promoters of TGF-β RI and 
TGF-β RII or mutations in the TGF-β RII promoter that interfere with transcription factor 
binding may also result in transcriptional silencing (Amoroso, et al., 1998). Decreased TGF-β 
RII function results in resistance to the growth inhibitory activity of TGF-β, but other TGF-β 
responses may not be affected in a similar fashion because they may require different levels 
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of signaling (Chen et al., 1993; Fafeur et al., 1993). The tumor suppressor role of TGF-β RII 
has been demonstrated by expressing wildtype TGF-β RII in cancer cells that lack a 
functional TGF-β RII allele (Sun et al., 1994; Wang et al., 1995) or by over-expressing TGF-β 
RII in vitro (Turco et al., 1999). Enhanced expression of TGF-β RII seems to confer growth 
inhibition, to suppress anchorage independent growth, and to significantly reduce tumor 
formation in experimental mice compared with parental cells. Over-expression of TGF-β RI 
or TGF-β RII in transgenic mice also shows enhanced tumor suppressor activity (Cui et al., 
1996; Minn et al., 2005), while expression of dominant-negative forms of TGF-β RII increases 
tumor formation (Böttinger et al., 1997; Go et al., 1999).  
Some of the genes for Smad proteins that function as mediators of TGF-β signal 
transduction also have mutations and deletions that occur in human carcinomas. Mutations 
in the genes encoding Smad2 and Smad3 are relatively rare and seem to occur only in a 
limited number of lung and colon carcinomas for Smad2 (Riggens et al., 1996; Uchida et al., 
1996), and gastric cancer for Smad3 (Han et al., 2004). In contrast, mutational inactivation of 
Smad4 (DPC4) is prominent in pancreatic carcer (Hahn et al., 1996). Mutations of Smad4 can 
be detected in human colorectal cancer, especially in those patients with late stage, 
metastatic disease (Maitra et al., 2000). This suggests that Smad4 may play a central role in 
TGF-β-mediated tumor suppression. Inactivation of the genes encoding Smad2 and Smad4 
occurs by several means, including deletion of entire chromosome segments, small 
deletions, and frameshift, nonsense, or missense mutations (Massagué & Wotton, 2000; 
Massagué et al., 2000). Mutations in Smad4 are detected principally in pancreatic 
carcinomas, and in colon carcinomas, and in other types of carcinomas, although with less 
frequency. Inactivation of both alleles of Smad4 and haploinsufficiency of the Smad4 locus 
may contribute to the progression of pancreatic and gastric cancers (Luttges et al., 2000; Xu 
et al., 2000). The existence of Smad4 mutations in several juvenile polyposis families further 
supports the suggestion that Smad4 is a tumor suppressor (Howe, 1998). Inactivating 
mutations in Smad4 are also observed in conjunction with mutations in TGF-β RI and TGF-β 
RII (Grady et al., 1999). This suggests that Smad4 also has tumor suppressor activities that 
are not related to TGF-β signaling. Alterations of Smad signaling, and of phosphorylation of 
Smad2 in particular, are associated with poor prognosis in human breast carcinomas, colon 
carcinomas, and head and neck squamous cell carcinomas (Xie et al., 2002, 2003a, 2000b). 
Loss of Smad3 expression in gastric cancer tissues and cell lines increases susceptibility to 
tumorigenesis (Han et al., 2004). Introduction of Smad3 into human gastric cancer cells that 
do not express Smad3 restores responsiveness to TGF-β. In addition, loss of Smad4 
expression and/or activity may increase the Ras signaling pathway to result in tumor 
progression (Iglesias et al., 2004). A protein-based strategy has been used to rapidly identify 
the most common alterations in the TGF-β signaling pathway by combining measurements 
of the levels and the state of activation of Smad signaling intermediates with DNA-based 
diagnostic assays (Yan et al., 2000). A mechanism for TGF-β resistance has been identified in 
TGF-β refractory squamous cell carcinoma cell lines using this protein-based strategy. 
1.3 TGF-β and apoptosis 
Another mechanism by which the tumor suppressor activity of TGF-β is mediated is 
through the process of programmed cell death or apoptosis. Unlike the molecular 
mechanisms by which TGF-β participates in cell proliferation and differentiation that have 
been well described, the mechanisms by which TGF-β exerts its apoptotic effects are only 
poorly understood in comparison. TGF-β-dependent apoptosis is important in the 
www.intechopen.com
Signaling Mechanisms of Transforming Growth Factor-β (TGF-β)  
in Cancer: TGF-β Induces Apoptosis in Lung Cells by a Smad-Dependent Mechanism 
 
149 
elimination of damaged or abnormal cells from many normal tissues (Schuster and 
Krieglstein, 2002). For example, TGF-β is implicated to play a role in controlling liver size, 
and intravenous injection of TGF-β induces apoptosis in normal and regressing liver 
(Schulte-Hermann et al., 1993). Hepatic over-expression of TGF-β in transgenic mice causes 
apoptosis, as does treatment of primary hepatocytes with TGF-β. The apoptotic fate of cells 
after they are treated with TGF-β1 is often determined by cellular context and experimental 
conditions. For example, TGF-β acts as a death stimulus inducing apoptotic death in fetal 
hepatocytes and podocytes (Herrera et al., 2001; Schiffer et al., 2001), whereas it elicits pro-
survival activity to protect macrophages against apoptosis (Chin et al., 1999; Schlapbach et 
al., 2000). A regulated balance of cell division and apoptosis is required for normal 
morphogenesis, and alterations in these processes can lead to neoplastic transformation. Cell 
cycle progression and the onset of apoptosis have been connected in DNA-damaged cells 
through the analysis of the activation of the apoptotic cascade in p21Cip1-deficient HCT116 
colorectal cancer cells (Le et al., 2005; Pardali et al., 2005). DNA damage induces a similar 
level of p53 activation and proapoptotic Bcl-2 family member PUMA induction in p21Cip1-
deficient cells compared to wildtype isogenic counterparts. However, only p21Cip1-deficient 
cells show extensive cytochrome C release, mitochondrial membrane depolarization, and 
caspase activation. When ectopically expressed in p21Cip1-deficient cells, p21Cip1, p27Kip1, and 
p16Ink4a are all similarly effective at causing cell cycle arrest and inhibiting DNA damage-
induced apoptotic events. Application of TGF-β stimulates apoptosis in various epithelial 
cells. Preliminary findings show that TGF-β induces apoptosis through the regulation of the 
expression of various pro- and anti-apoptotic molecules, including p53, Bad, Bax, Bik, Bcl-2, 
and Bcl-XL (Motyl et al., 1998; Saltzman et al., 1998; Sanchez-Capelo, 2005; Teramoto et al., 
1998). TGF-β-induced apoptosis can also be mediated by caspases (Brown et al., 1998; Chen 
and Chang, 1997; Choi et al., 1998; Saltzman et al., 1998). The mitochondrial septin-like 
protein, Apoptosis-Related Protein in the TGF-β Signaling Pathway (ARTS), enhances cell 
death induced by TGF-β through activation of caspase 3 (Larisch et al., 2000). In addition, 
TGF-β-induced apoptosis is associated with the generation of reactive oxygen species 
(Albright et al., 2003). Antioxidants can block the TGF-β-induced apoptotic process. 
Resistance to apoptosis is one of the characteristics of cancer cells during progressive 
tumorigenesis. Apoptosis of human prostate cancer cells that is induced by TGF-β or over-
expression of Smad7 is caused by a specific activation of the p38 MAP kinase pathway that 
may occur in a TGF-β-activated kinase 1 (TAK1) and mitogen-activated protein kinase 
kinase 3 (MKK3)-dependent manner (Edlund et al., 2003). Members of the Mixed Lineage 
Kinase 3 (MLK3) family also mediate TGF-β-induced apoptosis in hepatoma cells (Kim et 
al., 2004). There is also strong evidence that the stress- and cytokine-inducible Growth 
Arrest and DNA Damage (GADD) inducible gene 45 protein (Mita et al., 2002; Takekawa & 
Saito, 1998; Takekawa et al., 2002; Yoo et al., 2003) and GADD153 protein (Park et al., 1992), 
also known as CCAAT/enhancer-binding Homologous Protein (CHOP) (Ron & Habener, 
1992), CCAAT/Enhancer-Binding Protein-zeta (C/EBP-ζ) (Hanson, 1998), and DNA 
Damage Inducible Transcript-3 (DDIT3) (Fornace et al., 1989), function in the p38 Mitogen-
Activated Protein Kinase (MAPK) pathway and induce apoptosis (Corazarri et al., 2003). It 
has also been shown that Smad-dependent expression of GADD45b is responsible for the 
delayed activation of p38 MAP kinase by TGF-β1 in pancreatic carcinoma cells (Takekawa et 
al., 2002). Activation of GADD45b by the TGF-β receptor/Smad signaling pathway also 
mediates the induction of proteoglycan biglycan expression by TGF-β, also with the 
involvement of mitogen activated protein kinase kinase 6 (MKK6) and p38 MAP kinase 
www.intechopen.com
 
Tumor Suppressor Genes 
 
150 
(Mita et al., 2005). The p38 MAP kinase and p160/Rho/ROCK pathways have a role in TGF-
β-mediated Smad-dependent growth inhibition of breast cancer cells (Kamaraju & Roberts, 
2005). Smad3 contributes in a non-redundant manner to the induction of apoptosis in the 
mammary gland, but is dispensible for TGF-β effects on proliferation and differentiation in 
this tissue. TGF-β-induced p160/Rho/ROCK activation is also involved in the inhibition of 
Cdc25A, with resulting cell cycle arrest. TGF-β also regulates radiation-induced apoptosis 
and this is reduced in TGF-β1 null mice along with decreased p53 phosphorylation. TGF-β 
regulates biglycan gene expression through p38 MAP kinase signaling downstream of the 
Smads that also requires the small GTPase Rac1 (Groth et al., 2005). However, TGF-β-
Receptor activated p38 MAP kinase also mediates Smad-independent responses in breast 
cancer cells (Yu et al., 2002). Non-Smad signal transducers that are under the control of TGF-
β provide quantitative regulation of the signaling pathway, and serve as nodes for cross-talk 
with other signaling pathways, such as Notch, tyrosine kinase, G-protein-coupled receptor 
kinases, and cytokine receptors (Moustakas & Heldin, 2005). One of the characteristics of 
cancer cells during progressive tumorigenesis is resistance to apoptosis (Hanahan & 
Weinberg, 2000). Increasing the sensitivity of tumor cells to anticancer therapy is tightly 
correlated with the induction of apoptosis by anticancer drugs. Thus, it would be promising 
for disease treatment, including lung cancer, to activate TGF-β-mediated apoptosis by 
modulating the function of TGF-β in specific normal and tumor cell types. 
1.4 TGF-β and lung 
There is accumulating evidence that TGF-β may have a role in lung cancer and in lung 
disease. For example, elevated levels of TGF-β1 have been shown in plasma and lung 
tumors of patients with advanced lung cancer, and the prognosis of lung cancer patients 
who showed positive TGF-β1 was poorer than that of patients who were negative for this 
growth factor (Kong et al., 1996; Takanami et al., 1997). Lung cancer patients who responded 
to radiation therapy showed a decrease in circulating TGF-β levels compared to patients 
with no response or stable disease (Vujaskovic and Groen, 2000). One potential function of 
TGF-β in lungs and airways is regulation of epithelial cell survival through apoptosis. TGF-
β1 treatment of lung bronchial BEAS-2B cells increased apoptosis in cells exhibiting 
overexpression of Smad2 or Smad 3 (Yanagisawa et al., 1998). TGF-β1 treatment also 
enhanced Fas-induced apoptosis of alveolar and airway epithelial cells, and Fas-mediated 
apoptosis of alveolar epithelial cells was reported to be associated with increased expression 
of TGF-β1 (Hagimoto et al., 2002; Hagimoto et al., 1997).  
Besides TGF-β1, interleukin (IL)-6 is a multifunctional cytokine that is produced by a variety 
of cells during infection, trauma, and immunological challenge (Kishimoto et al., 1995). IL-6 
has been shown to mediate many inflammatory processes in the lung (Taga, 1997), and its 
dysregulated release has been implicated in the pathogenesis of a variety of respiratory 
conditions, including interstitial lung diseases (Berger, 2002; Bhatia & Moochhala, 2004; 
Shahar et al., 1996). IL-6 has been reported to have different effects on apoptosis of 
fibroblasts from normal and fibrotic lungs, with fibrotic lung cells showing enhanced 
resistance to apoptosis (Moodley et al., 2003) and to induce an increase in expression and 
activity of cathepsin, a cysteine protease that plays a major role in lysosomal bulk 
proteolysis, protein processing, matrix degradation, and tissue remodeling in the lung, in 
A549 lung cells (Gerber et al., 2001). Earlier reports have examined cross-talk between TGF-
β and IL-6 in epithelial cells, with TGF-β playing a role in the negative regulation of IL-6 
signaling in intestinal epithelial cells (Walia et al., 2003), as well as activating IL-6 expression in 
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prostate cancer cells (Park et al., 2003). In addition, bronchial epithelial 16 cells that are 
undergoing apoptosis have been shown to produce significantly more TGF-β, but less IL-6, 
than non-apoptotic cells (Hodge et al., 2002). This suggests that increased production of TGF-β 
and decreased expression of IL-6 by lung epithelial cells may contribute to the inhibition of 
proliferation, squamous metaplasia, and reduction of inflammation in lung injury.  
Lung cancer is the most lethal type of lung injury/cancer for both men and women. In the 
United States, in 2007, the most recent year for which statistics are currently available, lung 
cancer accounted for more deaths than breast, prostate and colon cancer combined, 
according to the U.S. Cancer Statistics Working Group. In that year, 109,643 men and 93,893 
women were diagnosed with lung cancer, and 88,329 men and 70,354 women died from 
lung cancer. The National Cancer Institute estimates there were 222,520 new cases of lung 
cancer and 157,300 deaths from lung cancer in 2010. Currently, 85% of lung cancer patients 
die within 5 years of diagnosis. This reflects the urgent need for improved therapies. 
Targeting signal transduction pathways that affect therapeutic resistance is one approach to 
improve patient outcomes. In normal cells, signaling is tightly regulated and begins with the 
transduction of signals through growth factor receptors or integrins to intracellular kinase 
enzymes, culminating in the regulation of cellular processes. Precise regulation of processes 
like cell division and apoptosis is required for normal morphogenesis, and alterations in 
these processes can lead to cancer. Increasing the sensitivity of tumor cells to anticancer 
therapy is tightly correlated with induction of apoptosis by anticancer drugs. Thus, it would 
be promising for disease treatment, including lung cancer, to activate TGF-β-mediated 
apoptosis by modulating the function of TGF-β in specific normal and tumor cells. 
We reported earlier that apoptosis is significantly decreased in the bronchio-alvelolar 
epithelium of mice that are heterozygous for TGF-β1 (Tang et al., 1998). This is consistent 
with a role for endogenous TGF-β1 in regulating apoptosis in lung. Here, we examined the 
ability of immortalized normal lung alveolar type II epithelial C10 cells to respond to TGF-
β1 and the functionality of the TGF-β1 signal transduction pathway in these cells. Our 
findings show that TGF-β1-mediated signaling induces apoptosis in C10 cells by a Smad-
dependent mechanism that requires activation of p38 MAPK and inhibition of the AKT 
pathway induced by IL-6. Furthermore, the GADD family members GADD45b and 
GADD153 are mediators of p38 MAPK activation in the process of TGF-β1-mediated 
apoptosis. 
2. Materials and methods 
2.1 Cell culture and reagents 
Previously established non-tumorigenic C10 cells derived from normal mouse lung 
epithelium were obtained from Dr. A. Malkinson (University of Colorado, Denver, CO). 
Cells were cultured in CMRL-1066 medium (Invitrogen, San Diego, CA) containing 10% 
heat-inactivated fetal bovine serum (FBS). Gadd153-deficient and wildtype cells were grown 
in DMEM with 10% non-heat inactivated FBS (Zinszner et al., 1998). Cells were treated with 
5 ng/ml recombinant human TGF-β1 obtained from R&D Systems (Minneapolis, MN) in a 
vehicle of 4 mM HCl containing 1 ng/ml BSA or vehicle alone. Antibodies against phospho-
specific and total p38 MAPK, ERK, JNK and AKT were from Cell Signaling Technologies 
(Beverly, MA). Antibodies against SMAD7 and GADD153 were from Santa Cruz 
Biotechnology (Santa Cruz, CA) and anti-hemagglutinin antibodies were from Covance 
(Berkeley, CA). The MAPK inhibitor SB203580 was from Calbiochem (San Diego, CA). 
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2.2 Plasmid constructs 
The hamster Gadd153 promoter fragments have been described previously (Luethy et al., 
1990). The 5’-deletion constructs of the hamster Gadd153 promoter containing fragments -778 
to +21, -225 to +21 and -36 to +21 were used to generate a Luciferase assay system in the pGL3-
basic vector (Promega, Madison, WI). The 5’-deletion constructs (-165 to +21 and -105 to +21) 
of the hamster Gadd153 promoter were generated by PCR using the 5’-primers 
(GGATATCGTCAGTGCCAGCGTGCCG and GGATATCGTCAGTGCCAGCGTGCCG, 
respectively) and the 3’-primer (ggaagcttgtgtgagactcaggctactg) and subcloned into the  
pGL3-basic vector. The mouse Gadd153- expressing plasmid was made by RT-PCR 
amplification using the 5’-primer (CGAAGCTTCCAGAAGGAAGTGCATC) and the 3’-primer 
(CGGGATCCGGAGAGACAGACAGG). All constructs were verified by DNA sequencing. 
2.3 Transient transfection and Luciferase assays 
C10 cells were transfected with 1-2 μg/well of DNAs and 1 ng/well of Renilla Luciferase 
reporter plasmid pRLTK (Promega) to normalize transfection efficiencies using 
Lipofectamine 2000 (Invitrogen). After 18-24 hours, cells were treated with TGF-β1 or 
vehicle. After 18 hours, cells were lysed and Luciferase activity was measured using a dual-
luciferase reporter assay system (Promega). All assays were performed in duplicate.  
2.4 Generation of stable cell lines 
C10 cells were transfected with HA-tagged Gadd45b, antisense Gadd45b, Gadd153 or 
Smad7 expression plasmids. Twenty-four hours after transfection, and every 4 days 
thereafter, the medium was replaced with fresh selection medium containing neomycin 
G418 (Invitrogen) at 800-µg/ml for 2 weeks. Neomycin-resistant clones were then 
individually transferred and expanded. After two additional passages in selection medium, 
independent clones were cultured in standard medium. As a mock control, the pcDNA3 
empty vector was used to transfect C10 cells and selected in the presence of neomycin. 
2.5 Western blot analysis 
C10 cells were stimulated in the presence or absence of TGF-β1. Freshly collected cells were 
homogenized in lysis buffer containing 0.05 mM Tris-HCl pH 7.4, 0.25% Na-deoxycholate, 
150 mM NaCl and 1 mM EDTA with protease inhibitors. Equal amounts of cell lysates were 
heated at 70oC for 10 minutes in sample loading buffer, separated by electrophoresis and 
transferred to membrane filters. Membranes were blocked with 5% nonfat dry milk in TBST 
buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.05% Tween 20 for 1 hour at 
room temperature, washed in TBST and incubated with various primary antibodies 
overnight at 4oC. Membranes were then incubated with horseradish peroxidase-conjugated 
secondary antibody for 1 hour at room temperature, washed in TBST buffer and proteins 
were visualized by enhanced chemiluminescence according to the manufacturer’s directions 
(Pierce, Rockford IL). 
2.6 Detection of apoptosis 
For DNA fragmentation assays, the Apoptotic DNA Ladder kit (Roche Applied Sciences, 
Indianapolis, IN) was used according to the manufacturer’s directions. Apoptosis was also 
quantitated by a Cell Death Detection ELISA assay (Roche Applied Sciences). All data points 
for the Cell Death Detection ELISA assay were determined in triplicate. 
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2.7 Semi-quantitative and real-time reverse transcription-polymerase chain reaction 
amplification 
Total RNA was isolated from C10 cells using Trizol reagent according to the manufacturer’s 
directions (Invitrogen). Reverse transcription (RT) was performed, followed by 
amplification by polymerase chain reaction (PCR) with oligonucleotide primers including 
Gadd45b 5'-primer (gggggattttgcaatcttct) and 3'-primer (cggtgaggcgatcctga), Gadd153  
5’-primer (ccagtcagagttctatggc) and 3’-primer (catgcttggtgcaggctgac) and glucose 6-
phosphate dehydrogenase (G6PD) 5’-primer (actgcagttccgagacgtgg) and 3’-primer 
(cagaagaggcagagtatagatggtg). As an internal control, mRNA for glucose-6-phosphate 
dehydrogenase (G6pd) was also amplified. Relative quantification of the mRNA levels of 
the target genes was determined using the DDCT method (Schmittgen et al., 2008). Results 
were expressed as N-fold difference in treated relative to untreated sample. All assays were 
performed twice in duplicate in independent PCR amplification reactions.  
2.8 Interleukin-6 immunoassay 
The levels of IL-6 in the supernatant of cultured cells were quantitated using a mouse 
Quantikine system (R&D Systems). Each measurement was performed in triplicate and an 
average value was recorded as pg/ml. 
2.9 Statistics 
Results were expressed as means ± standard error (S.E.) and the differences between means 
of treated and control groups were analyzed using the Student’s t test for paired data. A 
value of p < 0.05 was considered to be significant. 
3. Results 
3.1 TGF-β1 mediates apoptosis in mouse lung C10 cells 
Mouse lung C10 cells are a stable cell line originally derived from a Balb/c mouse lung 
explant with characteristics of alveolar type II pneumocytes (Smith et al., 1984). These 
normal cells are not transformed, are non-tumorigenic, and contain only wildtype K-ras 
alleles (Malkinson et al., 1997). Here, we examined the responsiveness of TGF-β1 in C10 
cells. TGF-β1 addition to C10 cells transiently transfected with Smad2 (ARE)- or Smad3 
((SBE)4)-dependent constructs augmented the transcriptional activity of these constructs by 
11-fold and 1.6-fold, respectively (Figure 1A), indicating that C10 cells respond to TGF-β1 
and Smad signaling is functional. Dramatic morphological changes characteristic of 
apoptosis, including large vacuoles, cell shrinkage and cytoplasmic blebbing were observed 
at 48 hours after TGF-β1 addition (Fig. 1B). Treatment with TGF-β1 also induced a 150- to 
200-bp internucleosomal DNA cleavage that produced a DNA fragmentation laddering 
pattern by 48 hours, and that was also detected by ELISA assay (Figure 1C and 1D). 
3.2 TGF-β1 activates p38 MAPK 
The MAPK signaling pathway, including p38 MAPK, extracellular signal-regulated kinase 
(ERK), and c-Jun N-terminal kinase (JNK), has been implicated in many physiological and 
pathological processes, including apoptosis (Javelaude & Mauviel, 2005; Zavadil & 
Böttinger, 2005). To study the possible role of the MAPK pathway in TGF-β1-mediated 
apoptosis in lung cells, C10 cells were treated with exogenous TGF-β1, and activation of p38 
MAPK, ERK1/ERK2, and JNK was then also examined using antibodies specific for total 
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and phosphorylated forms of each protein kinase. As shown in Figure 2A, there was a 
dramatic activation of p38 MAPK that occurred by 48 hours and the timing of activation of 
p38 MAPK by TGF-β1 coincided with induction of apoptosis by TGF-β1 (Figure 1). 
Activation of ERK1/ERK2 showed complex patterns of reduction and induction that were 
only modest. No activation of JNK by TGF-β1 was detected (data not shown). 
 
 
Fig. 1. TGF-β1 induces apoptosis in mouse lung C10 cells. 
A, Effect of TGF-β1 on basal ARE-Luc and (SBE)4-Luc transcription in C10 cells. C10 cells 
were transiently transfected with Smad2(ARE)-Luc, Smad3((SBE)4)-Luc or 3TP-Lux 
Luciferase reporters and cultured in vehicle (open bars) or TGF-β1 (filled bars) for 18-h. 
Luciferase activity was normalized to Renilla Luciferase values. The pGL3-basic empty 
vector control is shown. The results shown are the means standard error (S.E.) of two 
independent experiments performed in triplicate. B, Morphology of C10 cells by phase 
contrast microscopy at 24- and 48 hours after addition of TGF-β1. Magnification: 200X. The 
apoptotic response was determined by examining the DNA fragmentation pattern by C, gel 
electrophoresis and D, Cell Death Detection ELISA assay at various times after treatment 
with TGF-β1. **, p < 0.001 versus control. 
Because of the dramatic activation of p38 MAPK and induction of apoptosis by TGF-β1 in 
C10 cells, we chose to examine the role of p38 MAPK in this delayed apoptosis with MAPK 
SB203580, a potent inhibitor of p38 MAPK. Treatment of C10 cells with SB203580 strongly 
inhibited TGF-β1-induced apoptosis at 48 hours as determined by DNA fragmentation 
(Figure 2B). Inhibition of TGF-β1-induced apoptosis by SB203580 by 66% at 48 hours was 
also detected by ELISA assay (Figure 2C). Treatment of C10 cells with SB203580 also 
abrogated the morphological changes characteristic of apoptosis that were observed after 48 
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hours (Figure 2D). Our findings suggest that p38 MAPK activation by TGF-β1 is involved in 
TGF-β1-mediated apoptosis in C10 cells. 
 
 
Fig. 2. Activation of p38 MAPK by TGF-β1 results in apoptosis in C10 cells. 
A, Time course of phosphorylation of endogenous p38 MAP and ERK kinases after 
stimulation by TGF-β1. Total cell lysates were prepared from untreated or TGF-β1-treated 
cells and used for immunoblotting. Phosphorylated (P) and non-phosphorylated forms of 
p38 MAPK and ERK are indicated in the upper and lower panels, respectively. B-D, Cells 
were treated with TGF-β1 or vehicle alone in the presence or absence of 10 µM SB203580. 
The apoptotic response of C10 cells was determined by examining the DNA fragmentation 
pattern by B, gel electrophoresis and C, ELISA assay. The results shown are the means S.E. 
of two independent experiments performed in triplicate. *, p < 0.001 versus control. D, 
Morphology of C10 cells by phase contrast microscopy at 48 hours after treatment with 
TGF-β1 and SB203580. Magnification: 200X. 
3.3 TGF-β1 increases Gadd45b mRNA 
Since induction of apoptosis by TGF-β1 and activation of p38 MAPK occurred at a late time 
after addition of TGF-β1 in C10 cells, we considered the possiblity that additional protein 
mediators may be needed to activate p38 MAPK in response to TGF-β1. Previous studies 
have suggested the stress- and cytokine-inducible GADD45 family proteins (GADD45a, 
GADD45b, and GADD45g) function as specific activators of MEKK4, a MAPK kinase 
upstream in the p38 MAPK pathway (Mita et al., 2002), and induce apoptosis (Takekawa & 
Saito, 1998). To test the possible involvement of GADD family proteins in TGF-β1-mediated 
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apoptosis in C10 cells, we first examined expression of Gadd mRNA transcripts following 
treatment with TGF-β1 in these cells. Semi-quantitative and real-time RT-PCR amplification of 
RNA showed that Gadd45b mRNA was rapidly and significantly increased 8- and 11-fold by 
30 minutes and 1 hour, respectively, after treatment with TGF-β1, before decreasing (Figure 3A 
and B). Expression of transcripts for Gadd45a or Gadd45g was detected in C10 cells by RT-
PCR only after extended amplification at much lower levels (data not shown). These results 
suggest that GADD45b may play a role in TGF-β1-mediated apoptosis in C10 cells. 
 
 
Fig. 3. TGF-β1 increases expression of Gadd45b mRNA in C10 cells. 
Time course of expression of Gadd45 mRNA transcripts after stimulation by TGF-β1 using 
A, semi-quantitative and B, quantitative real-time RT-PCR amplification. Total RNA was 
prepared, reverse-transcribed and equal amounts of first-strand cDNA were amplified by 
PCR with Gadd45a-, Gadd45b- and Gadd45g -specific primers. G6pd, glucose-6-phosphate 
dehydrogenase. B, Relative expression of the Gadd45b gene in C10 cells treated with TGF-
β1. The results shown are the means S.E. of two independent experiments performed in 
duplicate. *, p < 0.001 versus control. 
3.4 GADD45b enhances the timing and sensitivity of TGF-β1-mediated apoptosis 
Having demonstrated that p38 MAPK is activated and expression of Gadd45b mRNA is 
increased coordinately with the induction of apoptosis by TGF-β1 in C10 cells, we next 
investigated whether overexpression of GADD45b could affect activation of p38 MAPK and 
lead to apoptosis. To test this, C10 cells were stably transfected with a hemagglutinin  
(HA)-tagged Gadd45b expression plasmid or empty vector used as control. In 
GADD45b-expressing cells (G-45b), p38 MAPK was activated in the absence of TGF-β1 
treatment, while TGF-β-induced activation of p38 MAPK occurred in control cells (Figure 4A). 
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Fig. 4. Overexpression of GADD45b activates p38 MAPK and increases the sensitivity of C10 
cells to TGF-β1-mediated apoptosis. 
A, C10 cells were stably transfected with either an empty vector (Control) or a 
hemaggluttinin (HA)-tagged Gadd45b expression vector (G-45b). Total cell lysates prepared 
from the cells untreated or treated with TGF-β1 for 48 hours were analyzed by 
immunoblotting. Phosphorylated (P) and non-phosphorylated forms of p38 MAPK are 
shown in the upper and middle panels, respectively. Expression of HA-tagged GADD45b 
and actin is shown in the middle and lower panels, respectively. B, Sense Gadd45b 
transcripts in C10 cells stably transfected with either an empty vector (Control) or an 
antisense Gadd45b expression vector (AS-G-45b) were subjected to RT-PCR analysis. 
Following a 1 hour incubation of the cells in the presence or absence of TGF-β1, total RNA 
was prepared and subjected to RT-PCR amplification using primers specific to the sense 
Gadd45b transcript. G6pd, glucose-6-phosphate dehydrogenase. C, Phosphorylation of 
endogenous p38 MAPK in total cell lysates prepared from C10 cells stably transfected with 
either an empty vector (Control) or an antisense Gadd45b expression vector (AS-G-45b) and 
untreated or treated with TGF-β1 for 24- and 48 hours, was analyzed by immunoblotting. 
Phosphorylated (P) and non-phosphorylated forms of p38 MAPK are shown in the upper 
and lower panels, respectively. D, C10 cells stably transfected with either an empty vector 
(Control), a Gadd45b expression vector (G-45b) or an antisense Gadd45b expression vector 
(AS-G-45b) were treated with vehicle (open bars) or TGF-β1 for 24- (gray bars) and 48 hours 
(dark bars). DNA fragmentation was detected by ELISA assay. *, p < 0.01 versus control.  
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To confirm the effect of GADD45b on activation of p38 MAPK, C10 cells were stably 
transfected with antisense Gadd45b cDNA (AS-G-45b) to block expression of the 
endogenous Gadd45b gene. Antisense Gadd45b suppressed endogenous Gadd45b mRNA 
expression induced by TGF-β1 (Fig 4B), and p38 MAPK activity was substantially reduced 
48 hours after treatment with TGF-β1 in AS-G-45b cells compared to control cells (Figure 
4C). These results suggest that endogenous GADD45b has a role in p38 MAPK activation. 
Next, to test whether GADD45b plays a role as a mediator of apoptosis induced by TGF-β1, 
we examined the ability of these cells to undergo apoptosis with or without TGF-β1. 
Apoptosis increased by ~50% in G-45b cells compared to control cells in the absence of  
TGF-β1, and overexpression of GADD45b increased the appearance of apoptosis in C10 cells 
by 24 hours (Figure 4D). However, apoptosis induced by TGF-β1 decreased in AS-G-45b 
cells compared to control cells 48 hours after TGF-β1 addition (Figure 4D). This result 
suggests that expression of endogenous GADD45b is necessary for TGF-β-mediated p38 
MAPK activation and apoptosis 
3.5 TGF-β1 increases GADD153 mRNA 
Because TGF-β1-mediated apoptosis in C10 cells involves increased expression of 
Gadd45b mRNA only after 0.5- and 1 hour, it is possible that additional proteins may be 
involved in TGF-β1-mediated apoptosis in these cells. Besides GADD45b, 
GADD153/CAATT enhancer binding protein homologous protein (CHOP), another 
member of the GADD family, has been implicated in processes that initiate apoptosis 
(Corazzari et al., 2003; Maytin et al., 2001; Murphy et al., 2001). We investigated whether 
GADD153 has a role in TGF-β-mediated apoptosis in C10 cells. Semi-quantitative and 
real-time RT-PCR amplification showed that Gadd153 mRNA had a gradual, but 
sustained, increase after TGF-β1 addition (Figure 5A), and by 3 hours, there was a 1.5-fold 
increase in expression of Gadd153 mRNA that increased significantly to 11- and 9-fold by 
24- and 48 hours, respectively (Figure 5B). 
We next used actinomycin D and cyclohexamide to investigate whether TGF-β1-induced 
Gadd153 mRNA expression is transcriptionally regulated and requires prior de novo 
protein synthesis or not. The addition of actinomycin D, an inhibitor of transcription, 
inhibited TGF-β1-induced Gadd153 mRNA expression (Figure 5C), indicating that up-
regulation of Gadd153 expression is transcriptionally dependent. To address whether the 
induction of Gadd153 mRNA expression by TGF-β1 requires de novo protein synthesis, the 
effect of the protein synthesis inhibitor cyclohexamide was examined. Addition of 
cyclohexamide by itself caused an increase in Gadd153 mRNA levels (Figure 5C). The level 
of Gadd153 mRNA expression was not significantly changed by addition of cyclohexamide 
and TGF-β1 together compared to cyclohexamide alone. This suggests that although 
Gadd153 mRNA is regulated by TGF-β1 in C10 cells, the induction of GADD153 by TGF-β1 
depends on prior de novo protein synthesis events. The increase in Gadd153 mRNA level in 
the presence of cyclohexamide could be explained by an increase in mRNA stability or loss 
of transcriptional repressors by cyclohexamide. 
3.6 GADD153 expression increases with overexpression of GADD45b 
Since expression of Gadd45b mRNA is induced early by TGF-β1 in C10 cells, while induction 
of Gadd153 mRNA occurs more gradually and maximizes at a later time compared to 
Gadd45b mRNA, we examined whether GADD45b could affect the expression of GADD153. 
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To test this, we used C10 cells that we had previously stably transfected with a (HA)-tagged 
sense or antisense Gadd45b expression plasmid. The basal level of GADD153 protein  
in GADD45b-expressing cells (G-45b) increased in the absence of TGF-β1, and treatment of 
these cells with TGF-β1 showed further increased expression of GADD153 protein after 24 
hours (Figure 6A). However, antisense Gadd45b (AS-G-45b) significantly suppressed 
endogenous GADD153 protein expression in the absence of TGF-β1 in AS-G-45b cells. 
 
 
Fig. 5. TGF-β1 increases expression of Gadd153 mRNA in C10 cells. 
Time course of expression of Gadd153 mRNA transcripts after stimulation by TGF-β1 using 
A, semi-quantitative and B, real-time RT-PCR amplification. Total RNA was prepared, 
reverse-transcribed and equal amounts of the first-strand cDNA were subjected to PCR 
amplification with specific primers for Gadd153 or glucose-6-phosphate dehydrogenase 
(G6pd). The results shown are the means S.E. of two independent experiments performed in 
duplicate. *, p<0.005, **, p < 0.001 versus control. C, C10 cells were treated with actinomycin 
(Act D; 1 μg/ml) or cycloheximide (CHX; 5 μg/ml) 1 hour before TGF-β1 addition, and 
incubated for 24 hours with or without TGF-β1. Total RNA was prepared and subjected to 
real-time RT-PCR using a primer specific for the Gadd153 transcript. The results shown are 
the means S.E. of three independent experiments performed in duplicate.  
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Expression of GADD153 protein was induced by TGF-β1 in C10 cells stably transfected with 
antisense Gadd45b cDNA, but at levels that were markedly reduced compared to control 
C10 cells. These results suggest that GADD45b is capable of inducing Gadd153 expression in 
response to TGF-β1 in C10 cells through a direct or indirect route. The ability of TGF-β1 to 
stimulate GADD153 expression in AS-G-45b cells could be explained by a residual level of 
Gadd45b that may be sufficient to stimulate a level of GADD153 expression, or alternatively, 
both Gadd45b-dependent and Gadd45b-independent mechanisms may exist for stimulating 
GADD153 expression in C10 cells. 
To confirm that endogenous GADD45b has an effect on TGF-β1-induced expression of 
GADD153, we used a hamster Gadd153 promoter Luciferase reporter construct. 
Cotransfection of Gadd45b plasmid showed that increasing amounts of Gadd45b using 0.1-, 
0.5- and 1-μg of Gadd45b cDNA, augmented transcriptional activity of Gadd153-Luc, with 
maximal induction occurring using 0.5-μg (Figure 6B). As a control, cotransfection of 
Gadd45b plasmid had no effect on the transcriptional activity of the TGF-β1-responsive 
p3TP-Lux reporter. These results suggest that GADD45b is involved in transactivation of the 
Gadd153 promoter. 
Having shown that GADD45b increases the activity of the Gadd153 promoter, we next set 
out to determine the minimum region of the Gadd153 promoter that was required for 
induction of Gadd45b. To accomplish this, we utilized a hamster Gadd153 promoter 
construct (pGadd153-778-+21-Luc) and a series of deletion constructs (pGadd153-225-+21-
Luc, pGadd153-165-+21-Luc, pGadd153-105-+21-Luc and pGadd153-36-+21-Luc). Addition 
of 0.5-μg of Gadd45b cDNA augmented transcriptional activity of pGadd153-778-+21-Luc 3-
fold (Figure 6C). Deletion of the Gadd153 promoter up to position –225 still conferred 
induction by GADD45b. However, deletion of additional nucleotides from –165 to –36 of the 
Gadd153 promoter resulted in reduced ability of GADD45b to induce the Gadd153 
promoter. In addition, cotransfection of Gadd45b with p3TP-Lux showed a minimal effect 
similar to that of pGadd153-36-+21-Luc, indicating specificity of the effect of GADD45b on 
GADD153. This suggests the existence of a sequence that is responsive to the effects of 
GADD45b in region –778 to -225 of the Gadd153 promoter. 
3.7 Overexpression of GADD153 activates p38 MAPK and induces apoptosis in the 
absence of TGF-β1 
To address the role of GADD153 inTGF-β1-mediated apoptosis in lung cells, we next 
investigated whether overexpression of GADD153 could activate p38 MAPK and lead to 
apoptosis in the absence of TGF-β1 in C10 cells. To test this, C10 cells were stably transfected 
with a Gadd153 expression vector or empty vector. Figure 7A shows increased expression of 
GADD153 protein in C10 cells stably transfected with Gadd153 expression plasmid (G-153-1 
and G-153-2), but not in control cells. While TGF-β1 treatment induced p38 MAPK 
activation in control cells, p38 MAPK in GADD153-expressing cells (G-153-1, G-153-2) was 
activated even in the absence of TGF-β1 (Figure 7B). In GADD153-expressing cells, 
apoptosis in the absence of TGF-β1 exceeded that in control cells that had been treated with 
TGF-β1, and sensitivity to TGF-β1-induced apoptosis was increased (Figure 7C and D). To 
further explore the involvement of p38 MAPK activation in GADD153-expressing cells, we 
used the potent inhibitor of p38 MAPK, SB203580. Treatment of GADD153-expressing cells 
with SB203580 strongly inhibited TGF-β1-induced apoptosis at 48 hours (Figure 7D). Our 
results suggest that the induction of GADD153 by TGF-β1 is part of the TGF-β1-mediated 
apoptotic pathway, and is upstream of p38 MAPK in this pathway. 
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Fig. 6. Effect of GADD45b on transactivation of GADD153. 
A, C10 cells stably transfected with either an empty vector (Control), a sense Gadd45b 
expression vector (G-45b) or an antisense Gadd45b expression vector (AS-G-45b) were treated 
with TGF-β1 or vehicle for 24 hours, and total cell lysates were analyzed by immunoblotting 
using GADD153-specific antibodies. Immunoblotting with actin antibodies is shown in the 
lower panel. B, C10 cells were transiently cotransfected with 0.5-μg Gadd153 (–778-+21)-Luc of 
the hamster Gadd153 promoter or 3TP-Luc plasmid as a negative control with increasing 
amounts of the Gadd45b expression plasmid. Cells were harvested 30 hours after transfection 
and assessed for Luciferase activity. The results shown are the means S.E. of three independent 
experiments performed. *, p < 0.05; **, p < 0.01 versus control. C, C10 cells were transiently 
cotransfected with 0.5-μg of Gadd45b expression plasmid and 0.5-μg of deletion mutants of 
the hamster Gadd153 promoter, including pGadd153 (-778-+21)-Luc, pGadd153 (-225-+21)-
Luc, pGadd153 (-165-+21)-Luc, pGadd153 (-105-+21)-Luc and pGadd153 (-36-+21)-Luc (filled 
bars) along with p3TP-Lux (open bar). Luciferase activity was measured. The results shown 
are the means S.E. of two independent experiments performed in triplicate. 
3.8 GADD153 expression and TGF-β1-mediated apoptosis is blocked by Smad7 
It has previously been reported that GADD45b is activated by TGF-β1 in a Smad-dependent 
manner (Takekawa et al., 2002; Yoo et al., 2003). Our results showed that GADD153 
induction occurs through GADD45b, which in turn, activates p38 MAPK, and leads to 
apoptosis in the presence of TGF-β1 in C10 cells. These findings evoked the possibility that 
TGF-β1-mediated apoptosis in C10 cells may be mediated by the Smad pathway. To 
determine whether the Smad pathway was required for TGF-β-mediated signaling of 
apoptosis, we asked whether overexpression of Smad7, an inhibitory Smad, would inhibit 
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this effect in C10 cells. In the Smad7-overexpressing cells detected by Smad7 antibody, 
expression of GADD153 protein was below the level of detection, and TGF-β1 addition did 
not result in induction of GADD153 protein as it did in control cells (Figure 8A). The basal 
level of apoptosis and the sensitivity to TGF-β1-mediated apoptosis was significantly 
reduced in C10 cells that overexpressed Smad7 (Figure 8B). The morphological changes 
described earlier did not occur in Smad7-overexpressing C10 cells treated with TGF-β1 
(Figure 8C). This indicates that TGF-β1-mediated apoptosis is Smad-dependent and requires 
induction of GADD153. To confirm that induction of GADD153 is important in determining 
sensitivity of C10 cells to TGF-β1-mediated apoptosis, we tested the ability of GADD153 to 
affect apoptosis in C10 cells that overexpressed Smad7. Transient restoration of GADD153 in 
C10 cells expressing Smad7 significantly augmented apoptosis in the absence of TGF-β1 and 
the level of apoptosis was not significantly affected by TGF-β1 treatment (Figure 8D). This 
suggests that the induction of GADD153 expression is a necessary and sufficient step for the 
induction of apoptosis in C10 cells that overexpress Smad7. 
Sensitivity of C10 cells to TGF-β1-mediated apoptosis, we tested the ability of GADD153 to 
affect apoptosis in C10 cells that overexpressed Smad7. Transient restoration of GADD153 in 
C10 cells expressing Smad7 significantly augmented apoptosis in the absence of TGF-β1 and 
the level of apoptosis was not significantly affected by TGF-β1 treatment (Figure 8D). This 
suggests that the induction of GADD153 expression is a necessary and sufficient step for the 
induction of apoptosis in C10 cells that overexpress Smad7. 
3.9 TGF-β1 regulates IL-6 production through a Smad2-dependent pathway 
Since overexpression of Smad7 not only blocked the basal apoptosis, but also resulted in a 
significant decrease in TGF-β1-mediated apoptosis compared to vector transfected control 
cells, it may be that TGF-β1 inhibits cell survival signaling pathways as well as activates 
apoptosis signaling pathways in C10 cells in a Smad-dependent manner. Among the 
cytokines that have been shown to participate in cellular survival, IL-6 can activate the 
phosphotidyl inositol-3 kinase (PI3K)/AKT survival pathway (Sierra, 2005). In addition, IL-
6 modulates TGF-β1-induced apoptosis via the PI3K/AKT pathway (Chen et al., 1999). To 
investigate possible crosstalk between TGF-β1 and IL-6, we examined IL-6 production by 
C10 cells that stably overexpress Smad7. Basal production of IL-6 was found to be 5-fold 
higher in Smad7-overexpressing C10 cells compared to control cells (Figure 9A), and IL-6 
production increased by accumulation in Smad7-overexpressing C10 cells after addition of 
TGF-β1. In contrast, no significant change in IL-6 production occurred in control C10 cells 
after treatment with TGF-β1. This result suggests that inhibition of the Smad signaling 
pathway by Smad7 leads to increased production of IL-6 in C10 cells. 
To investigate whether serine/threonine kinase AKT, a downstream target of PI3K, is 
involved, we also examined activation of AKT in C10 cells overexpressing Smad7. Figure 9B 
shows phosphorylation, and thus activation, of AKT in Smad7-overexpressing C10 cells. 
Activation of AKT was maintained at the basal level for up to 24 hours after treatment with 
TGF-β1 in C10 cells that overexpress Smad7, while activation of AKT was not detected in 
control C10 cells. To address the effect of IL-6 on TGF-β1-induced apoptosis, C10 cells were 
treated with either TGF-β1 or increasing amounts of IL-6. TGF-β1 induced apoptosis, while 
addition of IL-6 increased the ability of C10 cells to survive without TGF-β1 (Figure 9C). The 
ability of IL-6 to promote cell survival in C10 cells was detected using an IL-6 concentration 
as low as 1-ng/ml, maximized these effects using 10-ng/ml IL-6 and sustained these effects 
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using 50- and 100-ng/ml IL-6. Next, to investigate whether IL-6 affects apoptosis induced by 
TGF-β1, C10 cells were treated with TGF-β1 and IL-6 in combination using concentrations of 
10-, 50- or 100-ng/ml of IL-6. In the presence of TGF-β1, no treatments with IL-6 protected 
C10 cells from apoptosis induced by TGF-β1 (Figure 9D). These findings suggest that IL-6 
promotes cell survival in the absence of TGF-β1 in C10 cells, but does not inhibit apoptosis 
induced by TGF-β1, and also suggest that the apoptotic pathway may be predominant over 




Fig. 7. Overexpression of GADD153 activates p38 MAPK and increases TGF-β1-mediated 
apoptosis in C10 cells. 
A, C10 cells were stably transfected with either an empty vector (Control) or a Gadd153 
expression vector (G-153-1 and G-153-2). Total cell lysates were isolated and 
immunoblotting was performed using GADD153-specific antibodies. Immunoblotting with 
actin antibodies is shown in the lower panel. B, Phosphorylation of endogenous p38 MAPK 
in total cell lysates prepared from C10 cells stably transfected with either an empty vector 
(Control) or a Gadd153 expression vector (G-153-1 and G-153-2) and treated with TGF-β1 or 
vehicle for 24- and 48 hours was analyzed by immunoblotting. Phosphorylated (P) and non-
phosphorylated forms of p38 MAPK are indicated in the upper and lower panels, 
respectively. C, C10 cells stably transfected with either an empty vector (Control) or a 
Gadd153 expression vector (G-153-1) were treated with vehicle (open bars) or with TGF-β1 
for 24- (gray bars) and 48 hours (dark bars). DNA fragmentation was detected by ELISA 
assay. *, p < 0.01; **, p < 0.001 versus control. D, C10 cells stably transfected with either an 
empty vector (Control) or a Gadd153 expression vector (G-153-1) were treated with vehicle 
(open bars), TGF-β1 (gray bars), 10 μM SB203580 (dark bars) or TGF-β1 and SB203580 in 
combination (lined bars) for 48 hours. DNA fragmentation was detected by ELISA assay. 
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Fig. 8. Overexpression of Smad7 blocks GADD153 expression and TGF-β1-mediated 
apoptosis. 
A, C10 cells were stably transfected with either an empty vector (Control) or a Flag-tagged 
Smad7 expression vector (Smad7) and treated with TGF-β1 for 24- and 48 hours. Total cell 
lysates were isolated and immunoblotting was performed using Smad7 and GADD153 
antibodies. Immunoblotting with actin antibodies is shown in the lower panel. B, C10 cells 
stably transfected with either an empty vector (Control) or a Smad7 expression vector 
(Smad7) were treated with vehicle (open bars) or with TGF-β1 for 24- (gray bars) and 48 
hours (dark bars). DNA fragmentation was detected by ELISA assay. *, p < 0.05, **, p, < 0.01 
versus control. C, Morphology of C10 cells stably transfected with either an empty vector 
(Control) or a Smad7 expression vector (Smad7) by phase contrast microscopy at 48 hours 
after treatment with or without TGF-β1. D, C10 cells stably transfected with a Smad7 
expression vector were transiently transfected with either an empty vector (Vector) or 
Gadd153 cDNA expression vector (Gadd153) and cultured with vehicle (open bars) or TGF-
β1 (filled bars) for 48 hours. DNA fragmentation was detected by ELISA assay. 
 ** p < 0.01 versus control. 
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Fig. 9. Overexpression of Smad7 increases IL-6 production in the presence or absence of 
TGF-β1. 
C10 cells were stably transfected with either an empty vector (Control) or a Flag-tagged 
Smad7 expression vector (Smad7). A, The cells were treated with TGF-β1 for the indicated 
times. Conditioned media were isolated and the level of IL-6 protein production was 
detected using a Quantikine assay as described in Materials and Methods. The results 
shown are the means S.E. of two independent experiments performed in triplicate. B, 
Time course of phosphorylation of endogenous AKT after stimulation by TGF-β1. Total 
cell lysates were prepared from untreated or TGF-β1-treated cells and used for 
immunoblotting. Phosphorylated (P) and non-phosphorylated total forms of AKT are 
indicated in the upper and lower panels, respectively. C,D, C10 cells were treated with 
vehicle (open bars) or TGF-β1 (filled bars) or IL-6 (1-, 10-, 50- or 100-ng/ml) (stippled 
bars) in C, or a combination of TGF-β1 and IL-6 (10-, 50- or 100-ng/ml) (stippled bars) in 









Fig. 10. Production of IL-6 in embryo fibroblasts derived from Smad2- and Smad3-deficient 
mice and their wildtype littermates. 
Embryo fibroblasts from A, Smad2 null, B, Smad2 wildtype, C, Smad3 null and D, Smad3 
wildtype mice were cultured with vehicle (open bars) or TGF-β1 (filled bars) for 24- and 48 
hours. Conditioned media were isolated and the level of secreted IL-6 protein in pg/ml was 
detected using a Quantikine assay as described in Materials and Methods. The results 
shown are the means S.E. of two independent experiments performed in duplicate.  
*, p < 0.01, **, p < 0.001 versus control. 
Finally, to determine which Smad affects expression of IL-6, we examined the secretion of 
IL-6 in embryo fibroblasts from Smad2- and Smad3-deficient mice and their wildtype 
littermates. Treatment of Smad2 null mouse embryo fibroblasts (MEFs) with TGF-β1 
demonstrated that production of IL-6 was enhanced by TGF-β1 7-fold by 24 hours that 
increased to 15-fold by 48 hours, while no change was detected in the amount of IL-6 that 
was produced from wildtype MEFs (Figure 10B). In contrast, no change in IL-6 production 
was detected in Smad3 null and wildtype MEFs after treatment with TGF-β1 for up to 48 
hours. This suggests that TGF-β1 regulates IL-6 production via Smad2, but not via Smad3, in 
C10 cells. 
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The present study was undertaken to investigate the potential effect of TGF-β1 on apoptosis 
in immortalized normal mouse lung C10 cells. We reasoned that it would be easier to 
understand the mechanism of TGF-β1-mediated apoptosis in normal epithelial cells in 
which the TGF-β1 signaling pathway was functional than in tumor cells in which the TGF-
β1 pathway may not be functional. Addition of TGF-β1 to C10 cells activated the p38 MAPK 
pathway, and the p38 MAPK inhibitor SB203580 significantly reduced the TGF-β1-mediated 
apoptotic response. These findings suggest that activation of p38 MAPK is involved in TGF-
β1-mediated apoptosis in C10 cells. It has been reported that stress-activated protein kinases 
like p38 MAPK can mediate pro-apoptotic signals from TGF-β Receptors in multiple cell 
types, including lung cells (Undevia et al., 2004). Interestingly, although ERK1/ERK2 and 
JNK activation is associated with TGF-β Receptor-mediated apoptosis in some cell types, 
addition of TGF-β1 to C10 cells had only a marginal effect on activation of ERK and no effect 
on JNK. Thus, ERK and JNK do not appear to play essential roles in TGF-β1-mediated 
apoptosis in these lung cells. 
TGF-β1-mediated apoptosis in C10 cells has revealed an unexpected degree of complexity. 
TGF-β1-mediated apoptosis in C10 cells is dependent on signaling through Smads and p38 
MAPK. The delayed kinetics of p38 MAPK activation in TGF-β1-mediated apoptosis in C10 
cells suggest that one or more additional components may be involved in this process. 
Earlier reports have provided strong evidence that GADD45b is a critical upstream 
component in the apoptotic pathway of TGF-β1 in human pancreatic carcinoma cells and 
mouse hepatocytes (Takekawa et al., 2004; Yoo et al., 2003). A recent report outlined a role 
for Smad3 and Smad4 in activating Gadd45b through its third intron to facillitate G2 
progression following addition of TGF-β1 (Major & Jones, 2004). We examined the expression 
of Gadd45b mRNA in response to TGF-β1 in C10 cells. As in earlier reports, TGF-β1 induces 
expression of GADD45b in C10 cells. Overexpression of GADD45b accelerates the 
appearance of apoptosis in C10 cells by at least 24 hours, and down-regulation of GADD45b 
expression with an antisense construct inhibits TGF-β-mediated apoptosis. These results 
suggest that GADD45b participates in TGF-β1-mediated apoptosis in C10 cells. 
The participation of GADD45b in TGF-β1-mediated apoptosis in C10 cells does not rule out 
the possible involvement of other factors that may cooperate with GADD45b in TGF-β1-
mediated apoptosis. The time interval between the initial induction of Gadd45b mRNA 
expression by TGF-β1 stimulation and the appearance of apoptosis suggest that other factors 
may be involved. We explored the possible involvement of other GADD family members, 
including GADD5a and GADD45g. However, transcripts for Gadd45a or Gadd45g in the 
absence or presence of TGF-β1 were detected only at very low levels in C10 cells. Earlier 
reports showed that the stress-inducible transcription factor GADD153/CHOP induced 
apoptosis in mammalian cells through p38 MAPK-dependent and –independent 
mechanisms (Corazzari et al., 2003; Maytin et al., 2001; Murphy et al., 2001). GADD153 has 
been implicated in apoptosis, and cells isolated from Gadd153 null mice have been shown to 
be resistant to apoptosis-inducing regimes (Zinszner et al., 1998). In our study, Gadd153 
mRNA had a gradual and sustained increase in Gadd153 mRNA after treatment with TGF-
β1 that reached a maximum at 24- to 48 hours. The timing of Gadd153 mRNA induction is 
consistent with the appearance of TGF-β1-mediated apoptosis in C10 cells. Addition of 
actinomycin D and cyclohexamide showed that up-regulation of GADD153 expression is 
dependent on transcription and requires de novo protein synthesis. This suggests that 
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although Gadd153 mRNA is regulated by TGF-β1 in C10 cells, the induction of GADD153 
by TGF-β1 depends on prior protein synthesis events. 
Our results demonstrate that expression of GADD153 protein is induced in C10 cells stably 
transfected with Gadd45b cDNA, while it is markedly reduced in antisense Gadd45b-
expressing cells compared to control C10 cells untreated or treated with TGF-β1. 
Cotransfection of Gadd45b plasmid with Gadd153-Luc showed that increasing amounts of 
Gadd45b cDNA augmented transcriptional activity of Gadd153-Luc. These results suggest 
that GADD45b has a role in transactivation of GADD153 expression in response to TGF-β1 
in C10 cells in a direct or indirect manner. This is the first report of regulation of GADD153 
by GADD45b. Our findings also show that the induction of GADD153 is sufficient to 
activate p38 MAPK and to trigger apoptosis in the absence of TGF-β1 in C10 cells. 
In this study, we also demonstrated that GADD153 induction by TGF-β1 and TGF-β1-
mediated apoptosis was completely inhibited in C10 cells when Smad signaling was blocked 
by Smad7. Transient restoration of GADD153 in C10 cells overexpressing Smad7 
significantly augmented apoptosis in the absence of TGF-β1, and the level of apoptosis was 
not affected by TGF-β1 treatment. Our results suggest that GADD153 is a determining factor 
in TGF-β1-mediated apoptosis in C10 cells and induction of GADD153 may be useful to 
potentiate apoptosis in cells in which the TGF-β1 signaling pathway is not functional or only 
minimally functional, which is often the case in tumor cells. 
In addition to the p38 MAPK regulated apoptosis pathway, we also identified crosstalk 
between TGF-β1 and IL-6 in C10 cells. In C10 cells that overexpress Smad7, the basal level of 
IL-6 production was higher than in control cells and activation of AKT occurred without 
TGF-β1. Addition of IL-6 alone resulted in increased survival, and IL-6 in combination with 
TGF-β1 failed to block apoptosis induced by TGF-β1. The slow kinetics of delayed onset of 
TGF-β1-induced apoptosis may be attributed to the activation of the PI3K/AKT cell survival 
pathway during the early stage of TGF-β treatment (Yu et al., 2002). Activation of the AKT 
pathway by TGF-β1 has been shown to be mediated by a p38 MAPK-mediated mechanism 
(Horowitz et al., 2004). Activation of AKT in response to TGF-β1 addition does not appear to 
play an important role in normal C10 cells, indicating that this pathway probably does not 
participate in delaying the onset of apoptosis. However, if events occur which lead to the 
overexpression of Smad7, and thus decreased Smad-dependent TGF-β1 signaling, the 
activation of AKT may play a more prominent role. It has been reported that overexpression 
of Smad7 induced tumorigeniciy in human colon carcinoma cells by blocking TGF-β-
induced growth inhibition and apoptosis (Halder et al., 2005). It appears that the TGF-
β1/p38 MAPK-mediated apoptosis pathway in which GADD45b and GADD153 participate 
as intermediates, plays a more prominent role than the IL-6/AKT pathway does in C10 cells 
as outlined in Figure 11. Although our scenario depicts direct activation of GADD153 by 
GADD45b, this may or may not occur. Other factors may be involved. In addition, the 
survival pathway may be a less frequently used pathway in normal C10 cells compared to 
the apoptosis pathway. The predominance of these pathways may also change in tumor 
cells. Future studies will be needed to examine he role of these alternative pathways and 
crosstalk signaling that may be involved or abrogated in tumor cells. 
TGF-β1 induces GADD45b expression in a Smad-dependent manner. GADD45b then 
activates GADD153, which, in turn, activates p38 MAPK. Activated p38 MAPK results in 
apoptosis. This may be the predominant pathway in C10 cells. Alternatively, TGF-β may 
down-regulate IL-6 production through Smad2-dependent signaling. Elevated IL-6 may be 
able to induce activation of AKT to block or reduce apoptosis and increase cell survival. If 
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Smad signaling is blocked by Smad7 or reduced by another agent or phenomenon, it may be 
sufficient to confer a pro-survival/apoptosis-resistant phenotype to C10 cells. 
 
 
Fig. 11. A possible mechanism of TGF-β1-mediated apoptosis in mouse lung epithelial C10 
cells. 
5. Conclusion 
Resistance to apoptosis has been shown to be one of the characteristics of cancer cells during 
progressive tumorigenesis (Hanahan & Weinberg, 2000). Thus, it would be promising for 
the treatment of cancer, to activate TGF-β1-mediated apoptosis by modulating the function 
of TGF-β1 in specific tumor cell types. Our study has shown that in lung C10 cells that 
overexpress GADD153, both the basal level and sensitivity to apoptosis are increased, 
suggesting that the induction of GADD153 is an important step in the sensitivity of these 
lung cells to apoptosis. Future studies will need to be performed to evaluate whether 
increased levels of GADD153 can be stimulated effectively to increase TGF-β-mediated 
apoptosis in lung tumor cells in which this does not occur or occurs less frequently, and 
thus, bring about their destruction, and an effective therapy that can be used in the 
treatment of lung cancer. 
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